{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T17:10:06Z","timestamp":1722618606512},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,9,14]],"date-time":"2008-09-14T00:00:00Z","timestamp":1221350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The hepatitis C virus (HCV) is hyper-endemic in injecting drug users. There is also excess HCV among non-injection drug users who smoke, snort, or sniff heroin, cocaine, crack, or methamphetamine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>To summarize the research literature on HCV in drug users and identify gaps in knowledge, we conducted a synthesis of the relevant research carried out between 1989 and 2006. Using rigorous search methods, we identified and extracted data from published and unpublished reports of HCV among drug users. We designed a quality assurance system to ensure accuracy and consistency in all phases of the project. We also created a set of items to assess study design quality in each of the reports we included.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified 629 reports containing HCV prevalence rates, incidence rates and\/or genotype distribution among injecting or non-injecting drug user populations published between January 1989 and December 2006. The majority of reports were from Western Europe (41%), North America (26%), Asia (11%) and Australia\/New Zealand (10%). We also identified reports from Eastern Europe, South America, the Middle East, and the Caribbean. The number of publications reporting HCV rates in drug users increased dramatically between 1989 and 2006 to 27\u201352 reports per year after 1998.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The data collection and quality assurance phases of the HCV Synthesis Project have been completed. Recommendations for future research on HCV in drug users have come out of our data collection phase. Future research reports can enhance their contributions to our understanding of HCV etiology by clearly defining their drug user participants with respect to type of drug and route of administration. Further, the use of standard reporting methods for risk factors would enable data to be combined across a larger set of studies; this is especially important for HCV seroconversion studies which suffer from small sample sizes and low power to examine risk factors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2288-8-62","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T06:13:29Z","timestamp":1221545609000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The HCV Synthesis Project: Scope, methodology, and preliminary results"],"prefix":"10.1186","volume":"8","author":[{"given":"Rebecca K","family":"Stern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina","family":"Lelutiu-Weinberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Des Jarlais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Scheinmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiela","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique R","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Flom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,14]]},"reference":[{"key":"298_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1017\/S0950268802007902","volume":"129","author":"K Roy","year":"2002","unstructured":"Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L: Monitoring hepatitis C virus infection among injecting drug users in the European Union: A review of the literature. Epidemiol Infect. 2002, 129: 577-585. 10.1017\/S0950268802007902.","journal-title":"Epidemiol Infect"},{"key":"298_CR2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3109\/10826089809062214","volume":"33","author":"H Hagan","year":"1998","unstructured":"Hagan H: Hepatitis C virus transmission dynamics in injection drug users. Subst Use Misuse. 1998, 33: 1197-1212.","journal-title":"Subst Use Misuse"},{"key":"298_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1081\/JA-100102640","volume":"36","author":"S Tortu","year":"2001","unstructured":"Tortu S, Neaigus A, McMahon J, Hagen D: Hepatitis C among noninjecting drug users: A report. Subst Use and Misuse. 2001, 36: 523-534. 10.1081\/JA-100102640.","journal-title":"Subst Use and Misuse"},{"key":"298_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.drugalcdep.2005.03.004","volume":"79","author":"CJ Howe","year":"2005","unstructured":"Howe CJ, Fuller CM, Ompad DC, Galea S, Koblin B, Thomas D, Vlahov D: Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug Alcohol Depend. 2005, 79: 389-95. 10.1016\/j.drugalcdep.2005.03.004.","journal-title":"Drug Alcohol Depend"},{"key":"298_CR5","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1002\/hep.1840360727","volume":"36","author":"BR Edlin","year":"2002","unstructured":"Edlin BR: Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002, 36: S210-219. 10.1002\/hep.1840360727.","journal-title":"Hepatology"},{"key":"298_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00005792-199507000-00005","volume":"74","author":"DL Thomas","year":"1995","unstructured":"Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE: Correlates of Hepatitis C Virus Infections Among Injection Drug Users. Medicine (Baltimore). 1995, 74: 212-20. 10.1097\/00005792-199507000-00005.","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 1","key":"298_CR7","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2005.11.007","volume":"44","author":"JK Rockstroh","year":"2006","unstructured":"Rockstroh JK: Influence of viral hepatitis on HIV infection. J Hepatol. 2006, 44 (Suppl 1): S25-7. 10.1016\/j.jhep.2005.11.007.","journal-title":"J Hepatol"},{"key":"298_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/01.aids.0000196164.71388.3b","volume":"20","author":"B Lumbreras","year":"2006","unstructured":"Lumbreras B, Jarrin I, del Amo J, Perez-Hoyos S, Muga R, Garcia-de la Hera M, Ferreros I, Sanvisens A, Hurtado I, Hernandez-Aguado : Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS. 2006, 20: 111-6. 10.1097\/01.aids.0000196164.71388.3b.","journal-title":"AIDS"},{"key":"298_CR9","first-page":"260","volume-title":"Hepatitis C: An Australian perspective","author":"J Hocking","year":"2001","unstructured":"Hocking J, Crofts N, Aitken C, MacDonald M: Epidemiology of the hepatitis C virus among injecting drug users. Hepatitis C: An Australian perspective. Edited by: Crofts N, Dore G, Locarnini S, (Eds). 2001, Victoria, Australia: IP Communications, 260-295."},{"key":"298_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-2893.2002.00339.x","volume":"9","author":"C Mathei","year":"2002","unstructured":"Mathei C, Buntinx F, van Damme P: Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat. 2002, 9: 157-73. 10.1046\/j.1365-2893.2002.00339.x.","journal-title":"J Viral Hepat"},{"issue":"Suppl 3","key":"298_CR11","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1097\/01.aids.0000192090.61753.d4","volume":"19","author":"H Hagan","year":"2005","unstructured":"Hagan H, Thiede H, Des Jarlais DC: HIV\/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS. 2005, 19 (Suppl 3): S199-S207. 10.1097\/01.aids.0000192090.61753.d4.","journal-title":"AIDS"},{"key":"298_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/02791072.2003.10400492","volume":"35","author":"JM McMahon","year":"2003","unstructured":"McMahon JM, Tortu S: A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs. 2003, 35: 455-60.","journal-title":"J Psychoactive Drugs"},{"key":"298_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2006.11.014","volume":"89","author":"R Scheinmann","year":"2007","unstructured":"Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jarlais D, Flom P, Strauss S: Non-injection drug use and Hepatitis C Virus: A systematic review. Drug Alcohol Depend. 2007, 89: 1-12. 10.1016\/j.drugalcdep.2006.11.014.","journal-title":"Drug Alcohol Depend"},{"key":"298_CR14","unstructured":"National Health and Nutrition Examination Survey III. Centers for Disease Control and Prevention. National Center for Statistics."},{"key":"298_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/bmj.317.7156.433","volume":"317","author":"I van Beek","year":"1998","unstructured":"van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM: Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study. BMJ. 1998, 317: 433-437.","journal-title":"BMJ"},{"key":"298_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2105\/AJPH.91.9.1350","volume":"91","author":"H Hagan","year":"2001","unstructured":"Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER: Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001, 91: 42-46.","journal-title":"Am J Public Health"},{"key":"298_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/aje\/155.7.645","volume":"155","author":"LE Thorpe","year":"2002","unstructured":"Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, Monterroso ER, Garfein RS: Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002, 155: 645-653. 10.1093\/aje\/155.7.645.","journal-title":"Am J Epidemiol"},{"key":"298_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/jhep.2001.25759","volume":"34","author":"JA Hahn","year":"2001","unstructured":"Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR: Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001, 34: 180-7. 10.1053\/jhep.2001.25759.","journal-title":"Hepatology"},{"key":"298_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/00365540152029936","volume":"33","author":"D Goldberg","year":"2001","unstructured":"Goldberg D, Burns S, Taylor A, Cameron S, Hargreaves D, Hutchinson S: Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle\/syringe exchange. Scand J Infect Dis. 2001, 33: 457-461. 10.1080\/00365540152029936.","journal-title":"Scand J Infect Dis"},{"key":"298_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2105\/AJPH.91.1.38","volume":"91","author":"VD Hope","year":"2001","unstructured":"Hope VD, Judd A, Hickman M, Lamagni T, Hunter G, Stimson GV, Jones S, Donovan L, Parry JV, Gill ON: Prevalence of hepatitis C among injection drug users in England and Wales: Is harm reduction working?. Am J Public Health. 2001, 91: 38-42.","journal-title":"Am J Public Health"},{"key":"298_CR21","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"D Stroup","year":"2000","unstructured":"Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D, Moher D, Becker B, Sipe T, Thacker S, for the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group: Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA. 2000, 283: 2008-2012. 10.1001\/jama.283.15.2008.","journal-title":"JAMA"},{"key":"298_CR22","first-page":"573","volume":"37","author":"A Judd","year":"2002","unstructured":"Judd A, Hickman M, Rhodes T: Transmission of hepatitis C \u2013 are noninjecting cocaine users at risk?. Subst Use Misuse. 2002, 37: 573-5.","journal-title":"Subst Use Misuse"},{"key":"298_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/aje\/kwf222","volume":"157","author":"DC Des Jarlais","year":"2003","unstructured":"Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Fridman SR, Monterroso E, Williams I, Garfein R: Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol. 2003, 157: 467-71. 10.1093\/aje\/kwf222.","journal-title":"Am J Epidemiol"},{"issue":"Suppl 3","key":"298_CR24","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/01.aids.0000192066.86410.8c","volume":"19","author":"DC Des Jarlais","year":"2005","unstructured":"Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, Smith L, Wethers J, Milliken J, Mildvan D, Yancowitz S, Freidman SR: Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990\u20132001. AIDS. 2005, 19 (Suppl 3): S20-5. 10.1097\/01.aids.0000192066.86410.8c.","journal-title":"AIDS"},{"key":"298_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/oxfordjournals.aje.a009792","volume":"149","author":"H Hagan","year":"1999","unstructured":"Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER: Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999, 149: 203-13.","journal-title":"Am J Epidemiol"},{"key":"298_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2105\/AJPH.91.9.1350","volume":"91","author":"H Hagan","year":"2001","unstructured":"Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER: Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001, 91: 42-6.","journal-title":"Am J Public Health"},{"key":"298_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/jhep.2002.35065","volume":"36","author":"CL Miller","year":"2002","unstructured":"Miller CL, Johnston C, Spittal PM, Li K, LaLiberte N, Montaner JSG, Schecter MT: Opportunities for Prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology. 2002, 36: 737-42. 10.1053\/jhep.2002.35065.","journal-title":"Hepatology"},{"key":"298_CR28","first-page":"743","volume":"36","author":"CL Miller","year":"2004","unstructured":"Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, Montaner JSG, Schecter MT: The Future Face of Coinfection \u2013 Prevalence and Incidence of HIV and Hepatitis C Virus Coinfection Among Young Injection Drug Users. JAIDS. 2004, 36: 743-9.","journal-title":"JAIDS"},{"key":"298_CR29","first-page":"889","volume":"165","author":"DM Patrick","year":"2001","unstructured":"Patrick DM, Tyndall MW, Cornelisse PGA, Li K, Sherlock C, Rekart M, Strathdee S, Currie S, Schecter M, O'Shaughnessy M: Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ. 2001, 165: 889-95.","journal-title":"CMAJ"},{"key":"298_CR30","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1177\/002204269102100406","volume":"21","author":"D Vlahov","year":"1991","unstructured":"Vlahov D, Anthony J, Munoz A, Margdick J, Nelson K, Celentano D, Solomon L, Polk B: The alive study: A longitudinal study of HIV-1 infection in intravenous drug users: Description of methods. Journal of Drug Issues. 1991, 21: 759-","journal-title":"Journal of Drug Issues"},{"issue":"Suppl 1","key":"298_CR31","first-page":"S15","volume":"30","author":"E Sogolow","year":"2002","unstructured":"Sogolow E, Peersman G, Semaan S, Strouse D, Lyles CM: The HIV\/AIDS Prevention Research Synthesis Project: scope, methods, and study classification results. JAIDS. 2002, 30 (Suppl 1): S15-29.","journal-title":"JAIDS"},{"key":"298_CR32","volume-title":"Paper presented at the annual meeting of the American Society of Criminology, Royal York, Toronto","author":"H Liberty","year":"2006","unstructured":"Liberty H, Taylor A: An examination of the accuracy of self-reported drug use. Paper presented at the annual meeting of the American Society of Criminology, Royal York, Toronto. 2006, [http:\/\/www.allacademic.com\/meta\/p33788_index.html] -10-05"},{"key":"298_CR33","volume-title":"The handbook of research synthesis","year":"1994","unstructured":"Cooper H, Hedges L, (Eds): The handbook of research synthesis. 1994, New York: Russell Sage Foundation"},{"key":"298_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/bmj.316.7125.140","volume":"316","author":"MSM Egger","year":"1998","unstructured":"Egger MSM, Schneider M, Smith G: Meta-analysis: Spurious Precision? Meta-analysis of obseravtional studies. BMJ. 1998, 316: 140-4.","journal-title":"BMJ"},{"key":"298_CR35","unstructured":"Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, Flom P: HCV Synthesis Project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. IJDP."}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-8-62.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2288-8-62\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-8-62","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-8-62.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:18:46Z","timestamp":1630448326000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/1471-2288-8-62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,14]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1186\/1471-2288-8-62","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,14]]},"assertion":[{"value":"21 March 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"62"}}